Beijing Sungen Biomedical Technology Co., Ltd.
June 16, 2025
Company Presentation
Cardiovascular
Beijing Sungen Biomedical Technology Co., Ltd is an innovation-driven, clinical-stage biotechnology company founded in 2018, dedicated to advancing human health through cutting-edge technologies. We are pioneering the development of First-in-Class (FIC) and Best-in-Class (BIC) antibody-based therapeutics, including monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs) and Antibody-oligonucleotide conjugates(AOCs). Supported by a team of dedicated researchers and management with successful biotechnology entrepreneur experiences, Sungen has developed major research and manufacturing platforms in-house, such as AI-powered drug discovery platform. We leverage our innovative technology platforms to transform targeted therapies, focusing on cardiovascular, tumor, and neurodegenerative diseases. It is our commitment to address critical unmet clinical needs and improve patient outcomes worldwide.
Company HQ City:
Beijing
Company HQ State:
Beijing
Company HQ Country:
China
Year Founded:
2018
Lead Product in Development:
SGC001 is well positioned to be the FIC antibody drug (mAb) for acute myocardial infarction (AMI). With a target validated by multiple renowned institutional labs worldwide, SGC001 is undergoing phase I clinical trial subject to approvals from both US FDA and China NMPA, indicating excellent safety and pharmacokinetic characteristics.
CEO
Mr.Changqing LIN
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
SGC001 is expected to complete clinical trail phase I by August of 2025.
What is your next catalyst (value inflection) update?
Aug, 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}